Small Animal Studies Core Shared Resource ABSTRACT The Small Animal Studies Core (SASC) combines the resources available through the previously reviewed Small Animal Imaging Core with a new Animal Tumor Models component. This combined resource provides exceptional quality services for City of Hope Comprehensive Cancer Center (COHCCC) members for basic and translational preclinical studies in cancer biology, anti-cancer drug development, and stem cell therapeutic development. The Small Animal Imaging component of the SASC provides consultation, advanced imaging equipment, imaging services, hands-on training for COHCCC members, and support for protocol and grant preparation. Current systems in the Imaging Laboratory include two units for bioluminescence/fluorescence optical imaging (Ami X and Lago X from Spectral Instruments Imaging) and a PET/SPECT/CT trimodal scanner (Inveon from Siemens). These systems support molecular-based imaging to allow for the monitoring of cellular processes and the non-invasive assessment of pharmacokinetics and pharmacodynamics of therapeutic agents. Often the imaging techniques and targeting agents utilized are directly transferable to the clinical setting. The Animal Tumor Models component of the SASC has established patient-derived xenograft (PDX) models of breast, colorectal, lung, sarcoma, and gastric cancers in collaboration with COHCCC physician scientists and has developed next-generation humanized mouse models for research in cancer immunotherapy and in vivo drug metabolism/toxicity studies. The development of PDX models supports precision medicine by allowing investigators to evaluate tumor growth and therapeutic response for individual patients. The Animal Tumor Models component also provides specialized drug delivery services, training for in vivo procedures, and support for protocol preparation and grant development. The SASC is co-directed by Dr. David Colcher, a Professor in the Department of Molecular Immunology, and Dr. Jun Wu, an Associate Research Professor of Comparative Medicine, and is supported by highly qualified staff that maintain and operate the instrumentation. Oversight is provided by an interdisciplinary faculty Advisory Committee, and user feedback through an annual survey. The SASC occupies three rooms within the 29,000 sq. ft. Parvin Building for animal experiments and two rooms in Huntington Lab for tumor cell and reagent preparation. iLab software is used to schedule services, monitor instrument use, and manage billing within the SASC. Over the previous five years, the SASC was used by 80 unique investigators, including 58 CC members. Of the 58 CC members, 48 (83%) had peer-reviewed funding. As of this report, the SASC provides ongoing support to 12 NIH-funded projects totaling $5.6M per year in direct costs to the COHCCC.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA033572-37
Application #
9849199
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-12-01
Budget End
2020-11-30
Support Year
37
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Beckman Research Institute/City of Hope
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Abeywardana, Tharindumala; Oh, Myungeun; Jiang, Lei et al. (2018) CARM1 suppresses de novo serine synthesis by promoting PKM2 activity. J Biol Chem 293:15290-15303
Sun, Virginia; Crane, Tracy E; Slack, Samantha D et al. (2018) Rationale, development, and design of the Altering Intake, Managing Symptoms (AIMS) dietary intervention for bowel dysfunction in rectal cancer survivors. Contemp Clin Trials 68:61-66
Li, Daneng; McCall, Linda M; Hahn, Olwen M et al. (2018) Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study. Breast Cancer Res Treat 171:325-334
Aslamy, Arianne; Oh, Eunjin; Ahn, Miwon et al. (2018) Exocytosis Protein DOC2B as a Biomarker of Type 1 Diabetes. J Clin Endocrinol Metab 103:1966-1976
Smith, Nicholas R; Swain, John R; Davies, Paige S et al. (2018) Monoclonal Antibodies Reveal Dynamic Plasticity Between Lgr5- and Bmi1-Expressing Intestinal Cell Populations. Cell Mol Gastroenterol Hepatol 6:79-96
Jandial, Rahul; Neman, Josh; Lim, Punnajit P et al. (2018) Inhibition of GLO1 in Glioblastoma Multiforme Increases DNA-AGEs, Stimulates RAGE Expression, and Inhibits Brain Tumor Growth in Orthotopic Mouse Models. Int J Mol Sci 19:
Herrera, A F; Palmer, J; Martin, P et al. (2018) Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Ann Oncol 29:724-730
Caserta, Enrico; Chea, Junie; Minnix, Megan et al. (2018) Copper 64-labeled daratumumab as a PET/CT imaging tracer for multiple myeloma. Blood 131:741-745
Choi, Audrey H; O'Leary, Michael P; Lu, Jianming et al. (2018) Endogenous Akt Activity Promotes Virus Entry and Predicts Efficacy of Novel Chimeric Orthopoxvirus in Triple-Negative Breast Cancer. Mol Ther Oncolytics 9:22-29
Kumar, B; Garcia, M; Weng, L et al. (2018) Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion. Leukemia 32:575-587

Showing the most recent 10 out of 1396 publications